Form 4: Turnstone Biologics Director Acquires Stock Options
SEC Form 4 Filing
Director Kanya Rajangam acquired 12,770 stock options in Turnstone Biologics Corp. on June 3, 2024.
Summary
- Kanya Rajangam, a director of Turnstone Biologics Corp., acquired 12,770 stock options on June 3, 2024.
- The exercise price of these options is $2.69.
- The options vest on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service.
- Following the transaction, Rajangam directly owns 12,770 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a director.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's a standard practice for publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of the transaction: acquisition of stock options. |
| 06/03/2025 | Earliest vesting date for the stock options. |
| 06/02/2034 | Expiration date of the stock options. |
| 07/02/2024 | Date of the signature on the Form 4 filing. |
Keywords
stock options, Form 4, insider trading, Turnstone Biologics, TSBX, director, Rajangam
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.